Replacement of an NH3 by an iminoether in transplatin makes an antitumor drug from an inactive compound

Molecular Pharmacology

Volumn 58, Issue 6, 2000, Pages 1525-1535

  Leng, Marc ^a   Locker, Daniel ^a   Giraud Panis, Marie Josèphe ^a   Schwartz, Annie ^a   Intini, Francesco P ^b   Natile, Giovanni ^b   Pisano, Claudio ^c   Boccarelli, Angelina ^b   Giordano, Domenico ^b   Coluccia, Mauro ^b,d  

^a CENTRE DE BIOPHYSIQUE MOLÉCULAIRE   (France)

^b UNIVERSITY OF BARI   (Italy)

^c Department of Oncology ^*  (Italy)

^d UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMMONIA; CISPLATIN; CYTOSINE; DNA; ETHER; GLUTATHIONE; GUANINE; PROTEIN; THIOUREA; TRANSPLATIN;

ANIMAL CELL; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; CONTROLLED STUDY; CROSS LINKING; CYTOTOXICITY; DNA BINDING; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; SHORT SURVEY;

EID: 0033664309     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.58.6.1525     Document Type: Short Survey

References (40)

1. Lability of monofunctional cis-platinum adducts: Role of DNA double helix
2. 195Pt NMR kinetic and mechanistic studies of cis- and trans-diamminedichloroplatinum(II) binding to DNA
3. +
4. Chemical versality of transplatin monofunctional adducts within multiple site-specifically platinated DNA
5. Production of functional rat HMG1 protein in Escherichia coli
6. Flexing DNA: HMG-box proteins and their partners
7. Cytotoxicity and DNA binding mode of new platinum-iminoether derivatives with different configuration at the iminoether ligands
8. Intrastrand crosslinks are not formed in the reaction between transplatin and native DNA: Relation with the clinical inefficiency of transplatin
9. Interstrand cross-links of trans-diamminedichloroplatinum(II) are preferentially formed between guanine and complementary cytosine residues
10. DNA conformational change produced by the site-specific interstrand cross-link of trans-diamminedichloroplatinum(II)
11. 2]
12. Detection of drug binding to DNA by hydroxyl radical footprinting. Relationship of distamycin binding sites to DNA structure and positioned nucleosomes on 5S RNA genes of Xenopus
13. 2]
14. In vitro and in vivo antitumour activity and cellular pharmacological properties of new platinum-iminiether complexes with different configuration at the iminoether ligands
15. A transplatinum complex showing higher antitumor activity than the cis congeners
16. Intrinsically bent DNA
17. Rates of platination of AG and GA containing double-stranded oligonucleotides: Insights into why cisplatin binds to GG and AG but not GA sequences in DNA
18. Targeting of nucleic acids by iron complexes
19. DNA sequence context and protein composition modulate HMG-domain protein recognition of cisplatin-modified DNA
20. Interaction of trans-diamminedichloroplatinum(II) with DNA: Formation of monofunctional adducts and their reaction with glutathione
21. Current status of structure-activity relationships of platinum anticancer drugs: Activation of the trans geometry
22. Comparison of chemical reactivity, cytotoxicity, interstrand cross-linking and DNA sequence specificity of bis(platinum) complexes containing monodentate or bidentate coordination spheres with their monomeric analogues
23. Metals in medicine
24. Structure, recognition and processing of cisplatin-DNA adducts
25. Recognition of DNA interstrand cross-links of cis-diamminedichloroplatinum(II) and its trans isomer by DNA-binding proteins
26. Synthesis and in vitro and in vivo antitumor activity of a series of trans platinum antitumor complexes
27. DNA bending at adenine.thymine tracts
28. GG versus AG platination: A kinetic study on hairpin-stabilized duplex oligonucleotides
29. Interstrand cross-links are preferentially formed at the d(GC) sites in the reaction between cisdiamminedichloroplatinum(II) and DNA
30. Interaction between cisplatin-modified DNA and the HMG boxes of HMG1: DNase I footprinting and circular dichroism
31. Interstrand cross-links in cisplatin- or transplatin-modified DNA
32. 2(amine)(isopropylamine)] compounds. Cytotoxic activity and apoptosis induction in ras-transformed cells
33. Trans-platinum compounds in cancer therapy: A largely unexplored strategy for identifying novel antitumor platinum drugs
34. Clinical status of cisplatin, carboplatin, and other platinum-based antitumor drugs
35. Basis for recognition of cisplatin-modified DNA by high-mobility-group proteins
36. NMR solution structure of a DNA dodecamer containing a transplatin interstrand GN7-CN3 cross-link
37. Molecular electrostatic potential of the nucleic acids
38. Crystal structure of double-stranded DNA containing the major adduct of the anticancer drug cisplatin
39. 2]
40. The response of cellular proteins to cisplatin-damaged DNA